T. Rowe Price Associates’s Merck MRK Stock Holding History

T. Rowe Price Associates’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.77B	Buy	23,042,842 +4,289,452	+23%	+$495M	0.32%	58
2025 Q4	$1.97B	Buy	18,753,390 +5,152,069	+38%	+$484M	0.21%	90
2025 Q3	$1.14B	Buy	13,601,321 +2,803,331	+26%	+$231M	0.12%	145
2025 Q2	$855M	Sell	10,797,990 -967,842	-8%	-$76.9M	0.1%	182
2025 Q1	$1.06B	Sell	11,765,832 -745,175	-6%	-$69.6M	0.13%	154
2024 Q4	$1.24B	Sell	12,511,007 -9,961,069	-44%	-$1.03B	0.14%	130
2024 Q3	$2.55B	Sell	22,472,076 -2,252,985	-9%	-$268M	0.29%	59
2024 Q2	$3.06B	Sell	24,725,061 -4,914,456	-17%	-$633M	0.37%	52
2024 Q1	$3.91B	Sell	29,639,517 -447,700	-1%	-$55.2M	0.48%	37
2023 Q4	$3.28B	Buy	30,087,217 +809,052	+3%	+$84M	0.44%	42
2023 Q3	$3.01B	Sell	29,278,165 -112,224	-0.4%	-$12.1M	0.44%	42
2023 Q2	$3.39B	Sell	29,390,389 -448,026	-2%	-$50.9M	0.47%	39
2023 Q1	$3.17B	Buy	29,838,415 +3,524,385	+13%	+$381M	0.48%	46
2022 Q4	$2.92B	Buy	26,314,030 +11,051,945	+72%	+$1.13B	0.47%	45
2022 Q3	$1.31B	Sell	15,262,085 -1,764,865	-10%	-$158M	0.22%	94
2022 Q2	$1.55B	Buy	17,026,950 +2,111,477	+14%	+$187M	0.2%	111
2022 Q1	$1.22B	Sell	14,915,473 -2,389,330	-14%	-$188M	0.12%	169
2021 Q4	$1.33B	Sell	17,304,803 -1,197,067	-6%	-$95.3M	0.12%	171
2021 Q3	$1.39B	Buy	18,501,870 +3,128,468	+20%	+$238M	0.13%	159
2021 Q2	$1.2B	Sell	15,373,402 -3,402,484	-18%	-$253M	0.11%	188
2021 Q1	$1.38B	Sell	18,775,886 -1,090,203	-5%	-$80.4M	0.14%	166
2020 Q4	$1.55B	Buy	19,866,089 +146,180	+0.7%	+$11.2M	0.16%	141
2020 Q3	$1.56B	Buy	19,719,909 +2,445,682	+14%	+$192M	0.18%	120
2020 Q2	$1.27B	Buy	17,274,227 +2,285,487	+15%	+$172M	0.16%	138
2020 Q1	$1.1B	Sell	14,988,740 -1,716,320	-10%	-$135M	0.17%	125
2019 Q4	$1.45B	Sell	16,705,060 -5,087,987	-23%	-$418M	0.19%	116
2019 Q3	$1.75B	Sell	21,793,047 -2,243,072	-9%	-$180M	0.25%	92
2019 Q2	$1.92B	Sell	24,036,119 -8,582,035	-26%	-$657M	0.27%	88
2019 Q1	$2.59B	Sell	32,618,154 -10,125,397	-24%	-$757M	0.38%	61
2018 Q4	$3.12B	Sell	42,743,551 -9,952,415	-19%	-$703M	0.53%	35
2018 Q3	$3.57B	Buy	52,695,966 +8,031,751	+18%	+$512M	0.52%	33
2018 Q2	$2.59B	Buy	44,664,215 +1,488,395	+3%	+$84M	0.4%	51
2018 Q1	$2.24B	Sell	43,175,820 -13,669,477	-24%	-$738M	0.36%	64
2017 Q4	$3.05B	Sell	56,845,297 -4,824,750	-8%	-$267M	0.5%	35
2017 Q3	$3.77B	Buy	61,670,047 +743,310	+1%	+$45.1M	0.64%	23
2017 Q2	$3.73B	Buy	60,926,737 +7,199,573	+13%	+$438M	0.67%	20
2017 Q1	$3.26B	Buy	53,727,164 +14,257,812	+36%	+$865M	0.61%	20
2016 Q4	$2.22B	Buy	39,469,352 +2,089,229	+6%	+$122M	0.44%	49
2016 Q3	$2.23B	Buy	37,380,123 +17,569,309	+89%	+$1.03B	0.45%	49
2016 Q2	$1.09B	Buy	19,810,814 +1,197,933	+6%	+$63.8M	0.23%	109
2016 Q1	$940M	Sell	18,612,881 -2,122,114	-10%	-$104M	0.2%	128
2015 Q4	$1.05B	Sell	20,734,995 -7,384,639	-26%	-$372M	0.22%	111
2015 Q3	$1.33B	Sell	28,119,634 -3,786,521	-12%	-$201M	0.29%	80
2015 Q2	$1.73B	Sell	31,906,155 -9,204,764	-22%	-$516M	0.36%	63
2015 Q1	$2.25B	Sell	41,110,919 -2,882,890	-7%	-$163M	0.47%	41
2014 Q4	$2.38B	Sell	43,993,809 -207,985	-0.5%	-$11.6M	0.51%	40
2014 Q3	$2.5B	Sell	44,201,794 -3,510,088	-7%	-$197M	0.55%	38
2014 Q2	$2.63B	Buy	47,711,882 +383,570	+0.8%	+$20.9M	0.57%	30
2014 Q1	$2.56B	Buy	47,328,312 +2,160,835	+5%	+$112M	0.58%	26
2013 Q4	$2.16B	Sell	45,167,477 -2,271,575	-5%	-$104M	0.49%	40
2013 Q3	$2.16B	Sell	47,439,052 -3,037,082	-6%	-$139M	0.54%	34
2013 Q2	$2.24B	Buy	+50,476,134	New	+$2.25B	0.6%	27

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates's MRK Position: Q1 2026 in Review

T. Rowe Price Associates increased its Merck (MRK) stake by 23% in Q1 2026, buying an estimated $495M and bringing the position to 23,042,842 shares worth $2.77B. The position accounts for 0.32% of the portfolio, ranked #58.

T. Rowe Price Associates first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.91B in Q1 2024. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

T. Rowe Price Associates held 23,042,842 shares of Merck worth $2.77B as of Q1 2026.
T. Rowe Price Associates bought 4,289,452 Merck shares in Q1 2026, an estimated $495M.
Merck made up 0.32% of T. Rowe Price Associates's portfolio in Q1 2026, its #58 holding.
T. Rowe Price Associates first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
T. Rowe Price Associates's Merck position peaked at $3.91B in Q1 2024.
3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.